Pipeline

Our Pipeline

Surface is developing multiple antibody immunotherapy candidates focused on enhancing both innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.

SRF373 / NZV930 CD73 Antibody

About the target

CD73 is an ectoenzyme that plays a key role in the generation of extracellular adenosine, a critical modulator of the immune response. Inhibition of CD73 reduces levels of immunosuppressive adenosine in the tumor microenvironment allowing key immune cells, including T cells, to attack the tumor.

About our antibody candidate

SRF373, also known as NZV930, is a fully human anti-CD73 antibody which has been shown in preclinical studies to inhibit CD73 enzymatic activity, reduce levels of adenosine, and increase the proliferation of T cell receptor-stimulated CD4+ T cells. Additionally, preclinical studies have provided compelling evidence of anti-tumor activity when combining a CD73 inhibitor with a PD-1 inhibitor.

We have granted Novartis worldwide development and commercialization rights to SRF373 and a Phase I clinical trial was initiated in June 2018.

 

SRF617 CD39 Antibody

About the target

CD39 is an enzyme critical to both the production of adenosine and the breakdown of adenosine triphosphate (ATP). The accumulation of adenosine leads to immunosuppression, whereas maintained levels of ATP increases T-cell proliferation, dendritic cell maturation and pro-inflammatory cytokine levels.

About our antibody candidate

SRF617 is a fully human anti-39 antibody designed to inhibit CD39 and thereby reduce extracellular adenosine and maintain extracellular levels of immunostimulatory ATP to promote anti-tumor immunity. Surface wholly owns the rights to SRF617. It is anticipated to be one of the first CD39 antibodies to enter the clinic.

 

SRF388 IL-27 Antibody

About the target

IL-27 is an immunosuppressive cytokine involved in resolving T-cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 and mRNA gene signatures are found in cancer and are associated with poor prognoses.

About our antibody candidate

SRF388 is a fully human anti-IL-27 antibody. In preclinical studies, treatment with SRF388 was observed to block IL-27 signaling and its downstream immunosuppressive signaling effects. Preclinical combination with a PD-1 inhibitor increased the production of key inflammatory cytokines. SRF388 also demonstrates preclinical anti-metastatic tumor activity.

Under Surface’s collaboration agreement with Novartis, Novartis has the right to purchase an option to the SRF388 program.

 

SRF231 CD47 Antibody

About the target

CD47 is overexpressed by multiple tumor types and functions as an important immune escape mechanism. CD47-overexpressing tumor cells communicate a “don’t eat me” signal (macrophage checkpoint), which prevents them from being engulfed and eliminated by macrophages. Because of the number of cancers that express CD47, it is a target with broad therapeutic potential.

About our antibody candidate

SRF231 blocks the CD47 signal and makes tumor cells vulnerable to macrophage attack. Preclinical studies of SRF231 have shown that it binds with high affinity to CD47, stimulates phagocytosis and the killing of cancer cells in vitro, and has potent anti-tumor activity preclinically, both as monotherapy and in combination settings. SRF231 does not induce detectable hemagglutination or phagocytosis of red blood cells, a potentially important safety advantage.